gemfibrozil and niacin

gemfibrozil has been researched along with niacin in 81 studies

Research

Studies (81)

TimeframeStudies, this research(%)All Research%
pre-199020 (24.69)18.7374
1990's23 (28.40)18.2507
2000's22 (27.16)29.6817
2010's15 (18.52)24.3611
2020's1 (1.23)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL1
McIntyre, TH; Shapiro, ML; Whitney, EJ; Wirebaugh, SR1
Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK1
Hunninghake, DB2
Miller, NE1
Glueck, CJ1
Brown, WV; Karmally, W; Smith, DA1
Clavey, V; Fruchart, JC; Marzin, D; Olivier, P; Plancke, MO; Sauzieres, J1
Kane, JP; Malloy, MJ2
Naito, HK1
Hirai, Y; Kawakami, M; Koyama, S; Mishima, Y; Mizutani, A; Morishita, S; Saito, T1
Davignon, J1
Blum, CB; Levy, RI1
Nikkilä, EA; Tikkanen, MJ1
Perry, RS1
Havel, RJ; Kane, JP1
Malinow, MR1
Gotto, AM; Jones, PH; Scott, LW1
Levy, RI; Schaefer, EJ1
Nash, DT1
Benson, VV; Borok, GM; Dudl, RJ; Epstein, A; Epstein, RS; Heys, JF; Menzin, J; Oster, G; Quinn, V1
Chin, MM; Jozefiak, E; Morales, E; Spinler, SA; Wilson, MD1
Gibson, CM; Pasternak, RC; Rosner, B; Sacks, FM; Stone, PH1
Crouse, JR; King, JM; Miller, NE; Morgan, TM; Spray, BJ; Terry, JG1
Kuo, PT1
Bays, H; Lansing, AM1
Grundy, SM; Vega, GL2
Hiatt, J; Schectman, G1
Spencer, GA; Whitney, EJ; Wirebaugh, S1
Stone, NJ1
Bambauer, R; Müller, UA; Schiel, R1
Farmer, JA; Gotto, AM1
Andrews, TC; Green, G; Kalenian, R; Personius, BE; Whitney, EJ1
Sinzinger, H1
Bays, HE; Dujovne, CA1
Gylys, KH1
Zema, MJ1
Blazing, MA; Guyton, JR; Hagar, J; Kashyap, ML; Knopp, RH; McKenney, JM; Nash, DT; Nash, SD1
Boden, WE; Pearson, TA1
Sprecher, DL1
Pearson, TA1
Breuer, HW1
Kamanna, VS; Kashyap, ML; Sakai, T1
Ascaso, JF; Felipe Pallardo, L; Fernández-Cruz, A; González Santos, P; Hernández Mijares, A; Mangas Rojas, A; Millán, J; Pedro-Botet, J; Pérez-Jiménez, F; Pía, G; Pintó, X; Plaza, I; Rubiés-Prat, J1
Brown, BG; Gotto, AM; Kolasa, MW; Krasuski, RA; Maranian, AM; Michalek, JE; Monick, E; Personius, BE; Whitney, EJ1
März, W1
Lim, SC; Sum, CF; Tavintharan, S1
Bloomgarden, ZT1
Patel, J1
Rembold, CM1
Chronos, NA; Garrett, BC; King, SB; Momary, KM; Superko, HR; Wood, PD1
Ford, ES; Li, C; Mokdad, AH; Pearson, WS; Zhao, G1
Dunn, FL1
Gupta, A; Guyomard, V; Myint, PK; Rehman, HU; Zaman, MJ1
Devendra, GP; Krasuski, RA; Whitney, EJ1
Pathak, RD; Pathak, SR; Poonuru, S; Vats, HS1
Cater, G; Devendra, GP; Krasuski, RA; Whitney, EJ1
Qandil, AM; Rezigue, MM; Tashtoush, BM1
Kamal, AK; Shaikh, Q1
Jacob, RF; Mason, RP1
Chen, L; Chen, SC; Tsui, L; Wu, SJ; Xie, W; Xu, S; Ye, P1

Reviews

28 review(s) available for gemfibrozil and niacin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
    JAMA, 1990, Dec-19, Volume: 264, Issue:23

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit Analysis; Drug Therapy, Combination; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol; Sensitivity and Specificity

1990
Drug treatment of dyslipoproteinemia.
    Endocrinology and metabolism clinics of North America, 1990, Volume: 19, Issue:2

    Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipoproteinemias; Niacin; Probucol

1990
Pharmacological intervention for altering lipid metabolism.
    Drugs, 1990, Volume: 40 Suppl 1

    Topics: Animals; Cholestyramine Resin; Coronary Disease; Gemfibrozil; Humans; Lipid Metabolism; Lipids; Niacin

1990
When to treat hyperlipidemia.
    Advances in internal medicine, 1988, Volume: 33

    Topics: Animals; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Neomycin; Niacin; Pentanoic Acids; Risk Factors; Triglycerides

1988
Reducing cardiac deaths with hypolipidemic drugs.
    Postgraduate medicine, 1987, Nov-01, Volume: 82, Issue:6

    Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Niacin; Patient Education as Topic; Pentanoic Acids; Probucol

1987
Contemporary recommendations for evaluating and treating hyperlipidemia.
    Clinical pharmacy, 1986, Volume: 5, Issue:2

    Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Phenotype; Probucol

1986
Treatment of hypercholesterolemia.
    Annual review of medicine, 1986, Volume: 37

    Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Mice; Middle Aged; Neomycin; Niacin; Pentanoic Acids; Pregnancy; Probucol; Rats

1986
The diagnosis and management of hyperlipidemia.
    Disease-a-month : DM, 1986, Volume: 32, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibrate; Colestipol; Coronary Disease; Dextrothyroxine; Dietary Fats; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Lipoproteins; Lipoproteins, LDL; Neomycin; Niacin; Pentanoic Acids; Probucol; Receptors, LDL; Triglycerides

1986
Pathogenesis and management of lipoprotein disorders.
    The New England journal of medicine, 1985, May-16, Volume: 312, Issue:20

    Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylomicrons; Colestipol; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Hypobetalipoproteinemias; Hypolipoproteinemias; Infant; Infant, Newborn; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Tangier Disease

1985
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
    Circulation, 1984, Volume: 69, Issue:5

    Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lactation; Lipoproteins; Lovastatin; Naphthalenes; Niacin; Pentanoic Acids; Pregnancy; Pregnancy Complications; Probucol; Tangier Disease; Triglycerides

1984
Dyslipidemia and coronary artery disease.
    Clinical cardiology, 1994, Volume: 17, Issue:10

    Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin; Probucol

1994
Lipid management: current diet and drug treatment options.
    The American journal of medicine, 1996, Oct-08, Volume: 101, Issue:4A

    Topics: Diet; Gemfibrozil; Humans; Hyperlipidemias; Niacin; Patient Education as Topic

1996
Choosing the right lipid-regulating agent. A guide to selection.
    Drugs, 1996, Volume: 52, Issue:5

    Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Triglycerides

1996
Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
    The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A

    Topics: Apolipoproteins B; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lovastatin; Male; Niacin

1998
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
    Deutsche medizinische Wochenschrift (1946), 1998, Sep-18, Volume: 123, Issue:38

    Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis

1998
Drug interactions of lipid-altering drugs.
    Drug safety, 1998, Volume: 19, Issue:5

    Topics: Contraindications; Drug Interactions; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Probucol; Resins, Plant

1998
Pharmacology department: pharmacologic approaches to abnormal blood lipids.
    The Journal of cardiovascular nursing, 2000, Volume: 14, Issue:2

    Topics: Anion Exchange Resins; Antioxidants; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Nursing Research; Patient Compliance

2000
Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
    The American journal of cardiology, 2000, Mar-01, Volume: 85, Issue:5

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Randomized Controlled Trials as Topic; Triglycerides

2000
Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
    The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A

    Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Drug Combinations; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Myocardial Infarction; Niacin; Ultrasonography

2000
Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol.
    The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A

    Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Combinations; Ethanol; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Lovastatin; Niacin

2000
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Current medical research and opinion, 2001, Volume: 17, Issue:1

    Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Niacin; Pyridines; Pyrroles; Risk Factors; Triglycerides

2001
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
    Advances in internal medicine, 2001, Volume: 47

    Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Multivariate Analysis; Niacin; Phenotype; Risk Factors; Triglycerides

2001
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004, Volume: 4, Issue:5

    Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Assessment

2004
Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
    Singapore medical journal, 2005, Volume: 46, Issue:10

    Topics: Apoproteins; Arteriosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clofibric Acid; Delayed-Action Preparations; Drug Therapy, Combination; Estrogen Replacement Therapy; Ethanol; Exercise; Gemfibrozil; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Niacin

2005
Dyslipidaemia in diabetes.
    Clinical evidence, 2006, Issue:15

    Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin

2006
Management of dyslipidemia in people with type 2 diabetes mellitus.
    Reviews in endocrine & metabolic disorders, 2010, Volume: 11, Issue:1

    Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides

2010
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs.
    Advances in therapy, 2010, Volume: 27, Issue:6

    Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Evidence-Based Practice; Ezetimibe; Fatty Acids, Omega-3; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Patient Selection; Phytosterols; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Treatment Outcome

2010

Trials

12 trial(s) available for gemfibrozil and niacin

ArticleYear
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
    Controlled clinical trials, 1995, Volume: 16, Issue:1

    Topics: Adult; Aged; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Follow-Up Studies; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Niacin; Patient Selection; Prospective Studies; Risk Factors; Treatment Outcome

1995
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
    Lancet (London, England), 1994, Oct-29, Volume: 344, Issue:8931

    Topics: Anticholesteremic Agents; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Gemfibrozil; Humans; Lipids; Male; Middle Aged; Niacin; Pravastatin; Treatment Outcome

1994
Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia.
    The American journal of medicine, 1994, Volume: 97, Issue:4

    Topics: Dietary Fats; Fasting; Gemfibrozil; Humans; Hypolipoproteinemias; Lipids; Lipoproteins, HDL; Male; Middle Aged; Niacin; Time Factors; Treatment Outcome; Triglycerides

1994
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    The International journal of artificial organs, 1995, Volume: 18, Issue:12

    Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life

1995
Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl.
    The American journal of cardiology, 1997, Oct-01, Volume: 80, Issue:7

    Topics: Aged; Brachial Artery; Cholestyramine Resin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Niacin; Reference Values; Vasodilation

1997
Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study.
    Journal of the American College of Cardiology, 2000, Mar-01, Volume: 35, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Hypolipoproteinemias; Male; Middle Aged; Niacin; Prospective Studies; Treatment Outcome

2000
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Archives of internal medicine, 2000, Apr-24, Volume: 160, Issue:8

    Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Double-Blind Method; Female; Fibrinogen; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Triglycerides

2000
Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.
    Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:11

    Topics: Apolipoprotein A-I; Apolipoprotein A-II; Arteriosclerosis; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Gemfibrozil; Hepatocytes; Humans; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Niacin; Tumor Cells, Cultured

2001
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
    Annals of internal medicine, 2005, Jan-18, Volume: 142, Issue:2

    Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin

2005
Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    The American journal of cardiology, 2009, Feb-01, Volume: 103, Issue:3

    Topics: Adolescent; Adult; Aged; Apolipoproteins; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Male; Middle Aged; Niacin; Triglycerides; Young Adult

2009
Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study.
    Journal of cardiovascular pharmacology and therapeutics, 2010, Volume: 15, Issue:4

    Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholestyramine Resin; Coronary Artery Disease; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lipoproteins, HDL; Male; Middle Aged; Niacin; Risk; Risk Factors; Treatment Outcome; Young Adult

2010
The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study.
    The American journal of the medical sciences, 2011, Volume: 341, Issue:5

    Topics: Aged; Anticholesteremic Agents; Body Mass Index; Cholestyramine Resin; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Lipids; Longitudinal Studies; Male; Metabolic Syndrome; Middle Aged; Military Personnel; Niacin; Treatment Outcome

2011

Other Studies

41 other study(ies) available for gemfibrozil and niacin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat

2016
A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin.
    Pharmacotherapy, 1992, Volume: 12, Issue:6

    Topics: Aged; Alanine Transaminase; Cholestyramine Resin; Colestipol; Creatine Kinase; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lipids; Lovastatin; Male; Middle Aged; Niacin; Retrospective Studies

1992
Choice of cholesterol-lowering drugs.
    The Medical letter on drugs and therapeutics, 1991, Jan-11, Volume: 33, Issue:835

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Lovastatin; Neomycin; Niacin; Probucol

1991
Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis.
    American heart journal, 1985, Volume: 110, Issue:5

    Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Arteriosclerosis; Body Weight; Cholesterol, HDL; Estrogens; Ethanol; Gemfibrozil; Niacin; Pentanoic Acids; Phenytoin; Physical Fitness; Pyrimidines; Risk; Smoking; Terbutaline; Vasodilator Agents

1985
Treating hyperlipidemia, Part III: Drug therapy.
    Geriatrics, 1987, Volume: 42, Issue:8

    Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Pravastatin

1987
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
    Atherosclerosis, 1988, Volume: 70, Issue:1-2

    Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fenofibrate; Gemfibrozil; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Mice; Mice, Inbred Strains; Niacin; Pentanoic Acids; Triglycerides

1988
Current and new therapy for hypercholesterolemia.
    The Journal of the American Osteopathic Association, 1988, Volume: 88, Issue:7

    Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol

1988
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
    Archives of internal medicine, 1988, Volume: 148, Issue:1

    Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Dietary Fats; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Male; Middle Aged; Niacin; Patient Compliance; Pentanoic Acids; Probucol; Risk Factors

1988
[Strains and species differences in experimental hyperlipidemia].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1986, Volume: 87, Issue:3

    Topics: Animals; Clofibrate; Disease Models, Animal; Gemfibrozil; Glycerides; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred Strains; Niacin; Pentanoic Acids; Pyridines; Rats; Rats, Inbred Strains; Species Specificity

1986
Medical management of hyperlipidemia and the role of probucol.
    The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16

    Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pentanoic Acids; Phenols; Probucol; Risk

1986
Rational drug therapy of the hyperlipoproteinemias, Part II.
    Rational drug therapy, 1986, Volume: 20, Issue:10

    Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Neomycin; Niacin; Pentanoic Acids; Probucol

1986
Current pharmacologic treatment of elevated serum cholesterol.
    Circulation, 1987, Volume: 76, Issue:3

    Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides

1987
Adverse effects of the treatment for hyperlipidemia.
    Cardiology clinics, 1986, Volume: 4, Issue:1

    Topics: Anion Exchange Resins; Anticholesteremic Agents; Bibliographies as Topic; Clofibrate; Diet; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Neomycin; Niacin; Pentanoic Acids; Physical Exertion; Probucol; Risk

1986
Addition to labeling of cholestyramine.
    FDA drug bulletin, 1985, Volume: 15, Issue:1

    Topics: Cholestyramine Resin; Clofibrate; Diet Therapy; Drug Labeling; Gemfibrozil; Humans; Hypolipidemic Agents; Niacin; Pentanoic Acids; Probucol; Thyroxine; United States; United States Food and Drug Administration

1985
Lipid-lowering drugs.
    The Medical letter on drugs and therapeutics, 1985, Aug-30, Volume: 27, Issue:695

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins; Neomycin; Niacin; Pentanoic Acids; Probucol; Triglycerides

1985
Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases.
    Postgraduate medicine, 1983, Volume: 73, Issue:4

    Topics: Adult; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Lipoproteins, HDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Triglycerides; Valerates

1983
Criteria for use of hypolipidemic agents in adults.
    American journal of hospital pharmacy, 1994, Nov-15, Volume: 51, Issue:22

    Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Niacin; Risk Factors

1994
Fish oil (omega-3 fatty acids) in treatment of hypertriglyceridemia. A practical approach for the primary care physician.
    The Journal of the Kentucky Medical Association, 1994, Volume: 92, Issue:3

    Topics: Aged; Clofibrate; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Lipids; Lovastatin; Niacin; Primary Health Care

1994
Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia.
    Archives of internal medicine, 1994, Jan-10, Volume: 154, Issue:1

    Topics: Gemfibrozil; Humans; Hypolipoproteinemias; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Niacin

1994
Choice of cholesterol-lowering drugs.
    The Medical letter on drugs and therapeutics, 1993, Mar-05, Volume: 35, Issue:891

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Probucol

1993
Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
    The American journal of medicine, 1996, Volume: 100, Issue:2

    Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Colestipol; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Niacin; Peripheral Vascular Diseases; Retrospective Studies; Treatment Outcome; Triglycerides

1996
Effect of a combination of gemfibrozil and niacin on lipid levels.
    Journal of clinical pharmacology, 1996, Volume: 36, Issue:8

    Topics: Diet Therapy; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Niacin; Retrospective Studies

1996
Choice of lipid-lowering drugs.
    The Medical letter on drugs and therapeutics, 1998, Dec-18, Volume: 40, Issue:1042

    Topics: Animals; Cholestyramine Resin; Coronary Disease; Estrogen Replacement Therapy; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Niacin

1998
Choice of lipid-regulating drugs.
    The Medical letter on drugs and therapeutics, 2001, May-28, Volume: 43, Issue:1105

    Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Niacin; Triglycerides

2001
How doubling up drugs saves lives. Why doctors increasingly deploy an array of medications all at once.
    Heart advisor, 2004, Volume: 7, Issue:6

    Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Gemfibrozil; Humans; Niacin

2004
Summaries for patients. Targeting cholesterol treatment toward increasing high-density lipoprotein levels.
    Annals of internal medicine, 2005, Jan-18, Volume: 142, Issue:2

    Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin

2005
[Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    MMW Fortschritte der Medizin, 2005, Apr-07, Volume: 147, Issue:14

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Metabolic Syndrome; Niacin; Risk Factors; Triglycerides

2005
2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment.
    Diabetes care, 2005, Volume: 28, Issue:11

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Drug Therapy, Combination; Gemfibrozil; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Quinolines; Simvastatin; Triglycerides

2005
To statin or to non-statin in coronary disease-considering absolute risk is the answer.
    Atherosclerosis, 2008, Volume: 200, Issue:2

    Topics: Acute Coronary Syndrome; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet; Fatty Acids; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Regression Analysis; Research Design; Risk

2008
Hypertriglyceridemia and its pharmacologic treatment among US adults.
    Archives of internal medicine, 2009, Mar-23, Volume: 169, Issue:6

    Topics: Adult; Female; Fenofibrate; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Niacin; Nutrition Surveys; Prevalence; United States; Young Adult

2009
Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin.
    Clinical medicine & research, 2011, Volume: 9, Issue:1

    Topics: Adult; Gemfibrozil; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Niacin; Severity of Illness Index; Triglycerides

2011
Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2011, Jun-14, Volume: 43, Issue:3

    Topics: Chromatography, High Pressure Liquid; Esters; Gemfibrozil; Half-Life; Humans; Hydrogen-Ion Concentration; Hydrolysis; Hyperlipidemias; Kinetics; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Niacin; Nicotinic Acids; Plasma; Prodrugs; Solubility; Spectroscopy, Fourier Transform Infrared; Temperature

2011
HDL cholesterol--how do I raise my patients good cholesterol?
    JPMA. The Journal of the Pakistan Medical Association, 2012, Volume: 62, Issue:6

    Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Gemfibrozil; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pakistan; Practice Guidelines as Topic

2012
Drugs for lipids.
    Treatment guidelines from the Medical Letter, 2014, Volume: 12, Issue:137

    Topics: Animals; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin

2014
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.
    Biochimica et biophysica acta, 2015, Volume: 1848, Issue:2

    Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Eicosapentaenoic Acid; Fenofibrate; Gemfibrozil; Glucose; Heptanoic Acids; Lipid Peroxidation; Lipid Peroxides; Membrane Lipids; Membranes, Artificial; Niacin; Pyrroles

2015
Adverse drug reactions of non-statin antihyperlipidaemic drugs in China from 1989 to 2019: a national database analysis.
    BMJ open, 2023, 05-30, Volume: 13, Issue:5

    Topics: Cholestyramine Resin; Drug-Related Side Effects and Adverse Reactions; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Niacin; Probucol

2023